Stem cell research, biodiversity, and genetically modified foods are just three facets of biotechnology that pose challenging policy questions. RAND biotechnology research has assessed the role of the U.S. National Bioethics Advisory Commission, explored the global technology revolution, examined pharmaceutical innovation, and studied health and medical research in several Western countries.
Research conducted by: RAND Infrastructure, Safety, and Environment; RAND Health; RAND Europe
All Items (15)
REPORT
This comparative analysis of English and U.S. forensic DNA databases and profiling attempted to confirm what many senior U.S. law enforcement officials believe: that the English criminal justice system has capitalized more fully on the crime-fighting potential of DNA evidence.
REPORT
This paper highlights key points from a high-level Forum organised and facilitated by the Office of Health Economics and RAND Europe that discussed spillover effects from biomedical and health research, and strategies to realise their benefits.
REPORT
This documented briefing provides an overview of the European Research Area and explores whether such an integrated research area exists in health and biomedical research. The report is supported by the Department of Health (England).
JOURNAL ARTICLE
The bespoke process to procure the biomedical research centres resulted in relatively low transaction costs, compared to more traditional routes into funding research centres.
JOURNAL ARTICLE
This briefing was presented at the 32nd Annual American Association for the Advancement of Science (AAAS) Forum on Science and Technology Policy on May 3-4, 2007 in Washington, D.C. It highlights findings of RAND foresight analysis of global technology trends, drivers, barriers, and social implications through 2020, highlighting, in particular, issues relevant to building science, technology and innovation capacity in developing nations.
REPORT
An examination of 29 countries' science and technology capacity indicates that the global technology revolution will continue unabated over the next 15 years, but some countries will be in a better position than others to take full advantage of it.
COMMENTARY
Published commentary by RAND staff.
COMMENTARY
Published commentary by RAND staff.
JOURNAL ARTICLE
Explores the potential effect on future innovation in biotechnology of a patent on a gene, which may cover a wide range of possible technological applications and be of unknown breadth when issued.
JOURNAL ARTICLE
In this essay, the authors discuss the issues surrounding patenting products of nature. The central legal problem is how to distinguish a natural substance, for example, naturally occurring DNA, from a patentable invention. The authors suggest that the substantial transformation test (STT) used in customs law might be able to make this distinction.
REPORT
Summarizes the issues that arose and the discussions held during the meetings of a 1998-1999 study group focusing on global governance of information technology and biotechnology.
PEOPLE
Natural Scientist
Ph.D. in biology and public policy, Georgia Institute of Technology; B.S. in marine science and biology, University of Tampa
PEOPLE
Senior Analyst
Ph.D. in science and technology policy, University of Sussex; M.Sc. (with distinction) in science and technology policy, University of Sussex; B.A. (magna cum laude) in biology (physiology), Northwestern University
RAND® is a registered trademark. Copyright © 1994-2012 RAND Corporation.